Apoptosis triggered by Myc-induced suppression of Bcl-XL or Bcl-2 is bypassed during lymphomagenesis

Molecular and Cellular Biology

Volumn 21, Issue 15, 2001, Pages 5063-5070

  Eischen, C M ^a   Woo, D ^a   Roussel, M F ^a   Cleveland, J L ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2; PROTEIN BCL X; PROTEIN MDM2; PROTEIN P53; RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CARCINOGENESIS; HEMATOPOIETIC CELL; LYMPHOID CELL; LYMPHOMA; MOUSE; NONHUMAN; ONCOGENE MYC; PRIORITY JOURNAL; PROMYELOCYTE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; TUMOR CELL;

ADP-RIBOSYLATION FACTOR 1; ANIMALS; APOPTOSIS; BCL-X PROTEIN; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL SURVIVAL; CELLS, CULTURED; LYMPH NODES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MYELOID CELLS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; RNA; STEM CELLS; TIME FACTORS; TRANSFORMATION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; DROMAIUS NOVAEHOLLANDIAE; MUS MUSCULUS;

EID: 0034953712     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.21.15.5063-5070.2001     Document Type: Article

References (64)

1. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
2. Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor-deficient mice
3. Myc oncogenes: Activation and amplification
4. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis
5. The role of p53 in tumour suppression: Lessons from mouse models
6. Apoptotic cell death induced by c-myc is inhibited by bcl-2
7. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells
8. Induction of cell cycle progression and acceleration of apoptosis are two separable functions of c-Myc: Transrepression correlates with acceleration of apoptosis
9. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
10. The MYC protein activates transcription of the alpha-prothymosin gene
11. Disruption of the ARF-Mdm2-53 tumor suppressor pathway in Myc-induced lymphomagenesis
12. Induction of apoptosis in fibroblasts by c-myc protein
13. Cooperative interaction between c-myc and bcl-2 proto-oncogenes
14. Expression of bcl-2 in Burkitt's lymphoma cell lines: Induction by latent Epstein-Barr virus genes
15. v-Myb of E26 leukemia virus up-regulates bcl-2 and suppresses apoptosis in myeloid cells
16. Bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice
17. BCL-2 family members and the mitochondria in apoptosis
18. Database of p53 gene somatic mutations in human tumors and cell lines: Updated compilation and future prospects
19. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines
20. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells
21. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
22. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
23. Evidence that c-myc mediated apoptosis does not require wild-type p53 during lymphomagenesis
24. Traps to catch unwary oncogenes
25. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF
26. Apoptosis and macrophage-mediated deletion of precursor B cells in the bone marrow of E mu-myc transgenic mice
27. c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release
28. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF
29. Down-regulation of bcl-2 is associated with p16INK4-mediated apoptosis in non-small cell lung cancer cells
30. Regulation of Bcl-2 expression by oncogenic Ras protein in hematopoietic cells
31. p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma
32. Bcl-2 rescues T lymphopoiesis, but not B or NK cell development, in common gamma chain-deficient mice
33. BCL-2 gene family and the regulation of programmed cell death
34. Enforced expression of Bcl-2 in monocytes rescues macrophages and partially reverses osteopetrosis in op/op mice
35. The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway
36. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins
37. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination
38. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the L(14; 18)
39. Hematopoietic malignancies demonstrate loss-of-function mutations of BAX
40. Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes
41. Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage
42. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo
43. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
44. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice
45. Targeted disruption of Bcl-2 alpha beta in mice: Occurrence of gray hair, polycystic kidney disease, and lymphocytopenia
46. P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance
47. c-Myc and apoptosis
48. Selective regulation of Bcl-XL by a Jak kinase-dependent pathway is bypassed in murine hematopoietic malignancies
49. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest
50. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype
51. BCL-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy
52. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein
53. Tumorigenic activity of the BCRABL oncogenes is mediated by BCL2
54. 1/S-promoting mechanism parallel to the pRb/E2F pathway
55. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
56. The ARF/p53 pathway
57. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2
58. E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells
59. P19(ARF) stabilizes p53 by blocking nucleocytoplasmic shuttling of Mdm2
60. A dominant interfering Myb mutant causes apoptosis in T cells
61. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair
62. Nucleolar Arf sequesters Mdm2 and activates p53
63. Reassessing the role of C-MYB in tumorigenesis
64. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization